Golimumab CNTO-148|cas:476181-74-5|西域试剂

Golimumab CNTO-148,99.68%

产品编号：Bellancom-P99111| CAS NO：476181-74-5| 分子式：| 分子量：

戈利单抗（CNTO-148）是一种有效的人IgG1 TNFα拮抗剂单克隆抗体。戈利单抗具有抗炎活性，并抑制IL-6和IL-1β的产生。戈利单抗通过靶向和中和TNF发挥作用，以防止软骨和骨的炎症和破坏。戈利单抗具有抗癌活性并诱导细胞凋亡。戈利单抗可用于类风湿关节炎、克罗恩病和癌症研究。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99111		￥3700.00	杭州北京（现货）
Bellancom-P99111		￥8500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Golimumab CNTO-148

产品介绍

Golimumab (CNTO-148) 是一种有效的人 IgG1 TNFα 拮抗剂单克隆抗体。Golimumab 具有抗炎活性，并抑制 IL-6 和 IL-1β 的产生。Golimumab 通过靶向和中和 TNF 来防止炎症发生和软骨或骨骼的破坏。Golimumab 具有抗癌活性并诱导细胞凋亡 (apoptosis)。Golimumab 可用于类风湿关节炎、克罗恩病和癌症研究。

生物活性

Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research.

体外研究

Golimumab (CNTO-148) (0.1-10 μg /mL; 24-72 hours; transmembrane TNFα–transfected Jurkat cells) induces reductions in the viability of transmembrane TNFα–expressing cells.
Golimumab (CNTO-148) (10 μg /mL; 48 hours; transmembrane TNFα–transfected Jurkat cells) induces apoptosis, increase the levels of active caspase-3 and induces apoptotic DNA fragmentation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Transmembrane TNFα–transfected Jurkat cells
Concentration:	0.1, 1 and 10 μg/mL
Incubation Time:	24, 48 and 72 hours
Result:	Reduced cell viability in a dose- and time-dependent manner.

Apoptosis Analysis

Cell Line:	Transmembrane TNFα–transfected Jurkat cells
Concentration:	10 μg /mL
Incubation Time:	48 hours
Result:	Had the percentage of apoptotic cells for 30.29%.

Western Blot Analysis

Cell Line:	Transmembrane TNFα–transfected Jurkat cells
Concentration:	10 μg /mL
Incubation Time:	48 hours
Result:	Increased the levels of active caspase-3 and induces apoptotic DNA fragmentation.

体内研究
(In Vivo)

Golimumab (CNTO-148) (24 mg/kg; i.h.; daily, for 7 days; swiss-albino healthy male mice) inhibits oxidative stress, apoptotic cell death inflammatory response, thus improving renal function. Golimumab reduces all markers of kidney injury and attenuates cell death.
Golimumab (CNTO-148) (1-10 mg/kg; i.p.;daily; for 4 weeks; Tg197 transgenic mouse model) relieves TNFα-induced arthritis in a mouse model of human.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Swiss-albino healthy male mice
Dosage:	24 mg/kg
Administration:	Subcutaneous injection; daily, for 7 days
Result:	Reduced serum parameters like BUN, NGAL creatinine, cystatin C, and urinary parameters like KIM-1, NAG, albumin clusterin.

Animal Model:	Swiss-albino healthy male mice
Dosage:	24 mg/kg
Administration:	Subcutaneous injection; daily, for 7 days
Result:	Inhibited oxidative stress, reduces MDA concentrations and increases the GSH and catalase levels.

Animal Model:	Swiss-albino healthy male mice
Dosage:	24 mg/kg
Administration:	Subcutaneous injection; daily, for 7 days
Result:	Inhibitd cisplatin-induced inflammation, decreased TNF-α, including IL-6, IL-1β, MCP-1, ICAM-1, and TGF-β1 levels and increases IL-10 concentrations, reduced caspase 3 in cisplatin injected mice kidneys.

Animal Model:	Tg197 transgenic mouse model
Dosage:	1 and 10 mg/kg
Administration:	Intraperitoneal injection;for 4 weeks
Result:	Reduced the arthritic index.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Swiss-albino healthy male mice
Dosage:	24 mg/kg
Administration:	Subcutaneous injection; daily, for 7 days
Result:	Reduced serum parameters like BUN, NGAL creatinine, cystatin C, and urinary parameters like KIM-1, NAG, albumin clusterin.

Animal Model:	Swiss-albino healthy male mice
Dosage:	24 mg/kg
Administration:	Subcutaneous injection; daily, for 7 days
Result:	Inhibited oxidative stress, reduces MDA concentrations and increases the GSH and catalase levels.

Animal Model:	Swiss-albino healthy male mice
Dosage:	24 mg/kg
Administration:	Subcutaneous injection; daily, for 7 days
Result:	Inhibitd cisplatin-induced inflammation, decreased TNF-α, including IL-6, IL-1β, MCP-1, ICAM-1, and TGF-β1 levels and increases IL-10 concentrations, reduced caspase 3 in cisplatin injected mice kidneys.

Animal Model:	Tg197 transgenic mouse model
Dosage:	1 and 10 mg/kg
Administration:	Intraperitoneal injection;for 4 weeks
Result:	Reduced the arthritic index.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Swiss-albino healthy male mice
Dosage:	24 mg/kg
Administration:	Subcutaneous injection; daily, for 7 days
Result:	Reduced serum parameters like BUN, NGAL creatinine, cystatin C, and urinary parameters like KIM-1, NAG, albumin clusterin.

Animal Model:	Swiss-albino healthy male mice
Dosage:	24 mg/kg
Administration:	Subcutaneous injection; daily, for 7 days
Result:	Inhibited oxidative stress, reduces MDA concentrations and increases the GSH and catalase levels.

Animal Model:	Swiss-albino healthy male mice
Dosage:	24 mg/kg
Administration:	Subcutaneous injection; daily, for 7 days
Result:	Inhibitd cisplatin-induced inflammation, decreased TNF-α, including IL-6, IL-1β, MCP-1, ICAM-1, and TGF-β1 levels and increases IL-10 concentrations, reduced caspase 3 in cisplatin injected mice kidneys.

Animal Model:	Tg197 transgenic mouse model
Dosage:	1 and 10 mg/kg
Administration:	Intraperitoneal injection;for 4 weeks
Result:	Reduced the arthritic index.

性状

Liquid

溶解性数据

运输条件

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

. Ueda N, et, al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. Inflamm Bowel Dis. 2013 May;19(6):1224-31. [Content Brief]

. Pavitrakar V, et, al. Amelioration of Cisplatin-induced Renal Inflammation by Recombinant Human Golimumab in Mice. Curr Pharm Biotechnol. 2022;23(7):970-977. [Content Brief]

. Shealy DJ, et, al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010 Jul-Aug;2(4):428-39. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

1. 物质的识别

产品名：	Golimumab
CAS号：	476181-74-5
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Golimumab
别名：	CNTO-148
分子式：
分子量：

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	Please store the product under the recommended conditions in the Certificate of Analysis.

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。

10. 生态资料

一般注意事项：

无可用资料。

11. 废弃处置

按照所在国家，省份，县市和地方的法规处置。

12. 运输信息

正确的运输名称：	无
非危险品运输：	这种物质被视为非危险品运输。

13. 法规信息

尚未有针对此产品作出的化学安全性评估。

14. 其他信息

[1]. Ueda N, et, al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. Inflamm Bowel Dis. 2013 May;19(6):1224-31.

[2]. Pavitrakar V, et, al. Amelioration of Cisplatin-induced Renal Inflammation by Recombinant Human Golimumab in Mice. Curr Pharm Biotechnol. 2022;23(7):970-977.

[3]. Shealy DJ, et, al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010 Jul-Aug;2(4):428-39.

Golimumab CNTO-148,99.68%

Golimumab CNTO-148

化学品安全说明书(MSDS)

质检证书(COA)

1. 物质的识别

2. 合成/成分数据

3. 急救措施

4. 消防措施

5. 泄漏应急处理

6. 处理和储存

7. 接触控制和个人防护

8. 稳定性和反应活性

9. 毒性资料

10. 生态资料

11. 废弃处置

12. 运输信息

13. 法规信息

14. 其他信息

在线咨询